RS68231B1 - Anti-epha4 antitelo - Google Patents
Anti-epha4 antiteloInfo
- Publication number
- RS68231B1 RS68231B1 RS20260740A RSP20260740A RS68231B1 RS 68231 B1 RS68231 B1 RS 68231B1 RS 20260740 A RS20260740 A RS 20260740A RS P20260740 A RSP20260740 A RS P20260740A RS 68231 B1 RS68231 B1 RS 68231B1
- Authority
- RS
- Serbia
- Prior art keywords
- antibody
- epha4
- human
- seq
- amino acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Claims (13)
1. Patentni zahtevi
1. Anti-EphA4 antitelo, pri čemu
anti-EphA4 antitelo obuhvata teške i lake lance, i obuhvata:
(a) CDR1 teškog lanca koji se sastoji od aminokiselinske sekvence prikazane u SEQ ID NO.
44;
(b) CDR2 teškog lanca koji se sastoji od aminokiselinske sekvence prikazane u SEQ ID NO.
27;
(c) CDR3 teškog lanca koji se sastoji od aminokiselinske sekvence prikazane u SEQ ID NO.
28;
(d) CDR1 lakog lanca koji se sastoji od aminokiselinske sekvence prikazane u SEQ ID NO.
29;
(e) CDR2 lakog lanca koji se sastoji od aminokiselinske sekvence prikazane u SEQ ID NO.
30; i
(f) CDR3 lakog lanca koji se sastoji od aminokiselinske sekvence prikazane u SEQ ID NO.
31.
2. Anti-EphA4 antitelo prema zahtevu 1, pri čemu, anti-EphA4 antitelo je humanizovano.
3. Anti-EphA4 antitelo prema zahtevu 1 ili 2, pri čemu
varijabilni region teškog lanca sastoji se od aminokiselinske sekvence prikazane u SEQ ID NO. 45, a
varijabilni region lakog lanca sastoji se od aminokiselinske sekvence prikazane u SEQ ID NO. 46.
4. Anti-EphA4 antitelo prema bilo kom od zahteva 1 do 3, pri čemu
konstantni region teškog lanca i konstantni region lakog lanca obuhvataju aminokiselinske sekvence dobijene od humanog antitela, pri čemu, konstantni region teškog lanca je opciono konstantni region humanog IgG.
5. Anti-EphA4 antitelo prema zahtevu 4, pri čemu
konstantni region humanog IgG je konstantni region humanog IgG<2>, pri čemu konstantni region humanog IgG<2>opciono obuhvata aminokiselinsku sekvencu prikazanu u SEQ ID NO.
47.
6. Anti-EphA4 antitelo prema zahtevu 4 ili 5, pri čemu
konstantni region lakog lanca je konstantni region humanog Igκ, pri čemu konstantni region humanog Igκ opciono obuhvata aminokiselinsku sekvencu prikazanu u SEQ ID NO.48.
7. Anti-EphA4 antitelo prema bilo kom od zahteva 1 do 6, pri čemu
anti-EphA4 antitelo obuhvata teški i laki lanac,
teški lanac obuhvata aminokiselinsku sekvencu prikazanu u SEQ ID NO.59, a
laki lanac obuhvata aminokiselinsku sekvencu prikazanu u SEQ ID NO.60, pri čemu je C-terminalni lizin teškog lanca opciono izbačen.
8. Izolovana nukleinska kiselina koja kodira anti-EphA4 antitelo prema bilo kom od zahteva 1 do 7.
9. Vektor koji obuhvata nukleinsku kiselinu prema zahtevu 8.
10. Ćelija domaćin koja obuhvata vektor prema zahtevu 9.
11. Postupak za proizvodnju anti-EphA4 antitela, koji obuhvata korak uzgajanja ćelije domaćina prema zahtevu 10.
12. Farmaceutska kompozicija koja sadrži anti-EphA4 antitelo prema bilo kom od zahteva 1 do 7.
13. Anti-EphA4 antitelo prema bilo kom od zahteva 1 do 7 za upotrebu u lečenju Alchajmerove bolesti.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019122982 | 2019-07-01 | ||
| PCT/JP2020/025465 WO2021002312A1 (ja) | 2019-07-01 | 2020-06-29 | 抗ＥｐｈＡ４抗体 |
| EP20834769.0A EP3995582B1 (en) | 2019-07-01 | 2020-06-29 | Anti-epha4 antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS68231B1 true RS68231B1 (sr) | 2026-07-31 |
Family
ID=74066003
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20260740A RS68231B1 (sr) | 2019-07-01 | 2020-06-29 | Anti-epha4 antitelo |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US10947313B2 (sr) |
| EP (1) | EP3995582B1 (sr) |
| JP (2) | JP6979147B2 (sr) |
| KR (1) | KR102953475B1 (sr) |
| CN (2) | CN113906050B (sr) |
| AR (1) | AR119303A1 (sr) |
| AU (1) | AU2020300205B2 (sr) |
| BR (1) | BR112021025161A2 (sr) |
| CA (1) | CA3139398A1 (sr) |
| CL (1) | CL2021003326A1 (sr) |
| CO (1) | CO2021016588A2 (sr) |
| ES (1) | ES3073217T3 (sr) |
| FI (1) | FI3995582T3 (sr) |
| IL (1) | IL287828A (sr) |
| JO (1) | JOP20210333A1 (sr) |
| LT (1) | LT3995582T (sr) |
| MA (1) | MA56466B1 (sr) |
| MX (1) | MX2021015298A (sr) |
| MY (1) | MY207780A (sr) |
| PE (1) | PE20220570A1 (sr) |
| PH (1) | PH12021553090A1 (sr) |
| PT (1) | PT3995582T (sr) |
| RS (1) | RS68231B1 (sr) |
| SG (1) | SG11202112433VA (sr) |
| SM (1) | SMT202600263T1 (sr) |
| TW (3) | TWI866304B (sr) |
| UA (1) | UA129772C2 (sr) |
| WO (1) | WO2021002312A1 (sr) |
| ZA (1) | ZA202108836B (sr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| KR20210124308A (ko) | 2019-01-30 | 2021-10-14 | 트루바인딩 아이엔씨. | 항-gal3 항체 및 이의 용도 |
| EP3995582B1 (en) | 2019-07-01 | 2026-04-22 | Eisai R&D Management Co., Ltd. | Anti-epha4 antibody |
| MX2022014786A (es) | 2020-05-26 | 2023-01-16 | Truebinding Inc | Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3. |
| US20240010735A1 (en) * | 2020-12-24 | 2024-01-11 | Eisai R&D Management Co., Ltd. | Therapeutic pharmaceutical composition for amyotrophic lateral sclerosis |
| CN118234864A (zh) * | 2021-11-11 | 2024-06-21 | 卫材R&D管理有限公司 | 抗EphA4抗体 |
| WO2025151607A1 (en) * | 2024-01-10 | 2025-07-17 | Santa Ana Bio, Inc. | Methods and compositions for treating autoimmune, allergic and inflammatory diseases |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1094731A (en) | 1911-06-06 | 1914-04-28 | Lucien Linden | Oxidizing process. |
| JP2824433B2 (ja) | 1988-12-09 | 1998-11-11 | 財団法人化学及血清療法研究所 | 新規なハイブリッドプロモーターおよびこれを組み込んだ外来遺伝子発現用ベクター |
| CA1339413C (en) | 1988-06-24 | 1997-09-02 | Junichi Miyazaki | Exogenous gene expression vector containing chick .beta.-actin gene promoter |
| JP3680114B2 (ja) | 1993-09-17 | 2005-08-10 | 敏一 中村 | 脳神経障害治療剤 |
| US5902732A (en) | 1995-10-04 | 1999-05-11 | Cytoscan Sciences Llc | Drug screening process measuring changes in cell volume |
| US20020068361A1 (en) | 1997-04-08 | 2002-06-06 | Douglas Clary | Methods of evaluating specific cellular functions of receptor protein tyrosine kinases in a ligand independent manner |
| AU6887698A (en) | 1997-04-08 | 1998-10-30 | Sugen, Inc. | Study and treatment of diseases related to specific cellular functions of receptor protein tyrosine kinases |
| US5876946A (en) | 1997-06-03 | 1999-03-02 | Pharmacopeia, Inc. | High-throughput assay |
| US20070026409A1 (en) | 2001-08-14 | 2007-02-01 | The General Hospital Corporation | Nucleic acid and amino acid sequences involved in pain |
| AU2002324700A1 (en) | 2001-08-14 | 2003-03-03 | Bayer Ag | Nucleic acid and amino acid sequences involved in pain |
| US20060241074A1 (en) | 2001-08-14 | 2006-10-26 | The General Hospital Corporation | Methods for treatment of pain |
| JP2003169699A (ja) | 2001-12-10 | 2003-06-17 | Japan Science & Technology Corp | 特異的γプロテアーゼ阻害剤のスクリーニング方法 |
| JP2004000060A (ja) | 2002-05-31 | 2004-01-08 | Otsuka Pharmaceut Co Ltd | アミロイドβ産生に影響を与える化合物のスクリーニング方法 |
| JP2006507256A (ja) | 2002-09-24 | 2006-03-02 | ザ バーナム インスティチュート | Ｅｐｈ受容体活性を調節する新規薬剤 |
| HRP20050461A2 (en) | 2002-11-26 | 2005-08-31 | Pharmacia & Upjohn Company Llc | Soluble notch-based substrates for gamma secretase and methods and compositions for using same |
| WO2005048917A2 (en) | 2003-06-06 | 2005-06-02 | Medimmune, Inc. | Use of epha4 and modulator or epha4 for diagnosis, treatment and prevention of cancer |
| CN1878865A (zh) | 2003-11-10 | 2006-12-13 | 财团法人大阪产业振兴机构 | 无细胞Notch切割分析方法以及药物筛选方法 |
| EP1730279A2 (en) | 2004-02-27 | 2006-12-13 | Oncotherapy Science, Inc. | Epha4 as therapeutic target of prc and pdaca |
| NZ553273A (en) | 2004-09-08 | 2009-11-27 | Univ Melbourne | Treating gliosis, glial scarring, inflammation or inhibition of a xonal growth in the nervous system with an antagonist of EphA4-mediated signalling |
| EP1662259A1 (en) | 2004-11-25 | 2006-05-31 | Cellzome Ag | Use of Eph receptor inhibitors for the treatment of neurodegenerative diseases |
| GB0427023D0 (en) | 2004-12-09 | 2005-01-12 | Merck Sharp & Dohme | Assay method |
| CN101432022A (zh) | 2006-02-28 | 2009-05-13 | 肿瘤疗法科学股份有限公司 | 利用抗-EphA4抗体效应物作用损伤细胞的方法 |
| EP1947193A1 (en) | 2007-01-17 | 2008-07-23 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Screening method for anti-diabetic compounds |
| EP2166110B1 (en) | 2007-06-08 | 2012-02-22 | Eisai R&D Management Co., Ltd. | Screening method utilizing novel substrate epha4 for gamma-secretase |
| EP2183598A1 (en) | 2007-07-13 | 2010-05-12 | Elan Pharmaceuticals Inc. | Compositions and methods for identifying substrate specificity of inhibitors of gamma secretase |
| EP2177623A4 (en) | 2007-07-19 | 2010-12-29 | Eisai R&D Man Co Ltd | SCREENING METHOD USING C-MET, A NEW SUBSTRATE FOR GAMMA SECRETASE |
| WO2009017234A1 (ja) | 2007-08-01 | 2009-02-05 | Eisai R & D Management Co., Ltd. | γ-セクレターゼの新規基質c-Retを利用したスクリーニング方法 |
| EP2031064A1 (de) | 2007-08-29 | 2009-03-04 | Boehringer Ingelheim Pharma GmbH & Co. KG | Verfahren zur Steigerung von Proteintitern |
| US20090163594A1 (en) | 2007-10-31 | 2009-06-25 | Elan Pharmaceuticals, Inc. | Triple Assay System for Identifying Substrate Selectivity of Gamma Secretase Inhibitors |
| US8530181B2 (en) | 2007-11-15 | 2013-09-10 | Eisai R&D Management Co., Ltd. | Method of screening for compounds which affect the cleavage of EphA7 byγ-secretase |
| US7892769B2 (en) | 2007-11-30 | 2011-02-22 | Eisai R&D Management Co., Ltd. | Processing of EphA4 polypeptide by γ-secretase activity |
| US20100113415A1 (en) | 2008-05-29 | 2010-05-06 | Rajapakse Hemaka A | Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer |
| EP2260864A1 (en) | 2009-06-10 | 2010-12-15 | University of Melbourne | Therapeutic applications |
| JP2010285413A (ja) | 2009-06-10 | 2010-12-24 | Univ Of Melbourne | 治療用途 |
| WO2012081502A1 (ja) | 2010-12-17 | 2012-06-21 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ゼラチナーゼによるEphA4の切断反応を指標としたスクリーニング方法 |
| US9784751B2 (en) | 2011-04-25 | 2017-10-10 | Eisai R&D Management Co., Ltd. | Method for detecting neurological disease associated with cognitive impairment by measuring EphA4 extracellular domain |
| GB201107996D0 (en) | 2011-05-13 | 2011-06-29 | Vib Vzw | EphA4 is a diease modifier in motor neuron disease |
| WO2015007222A1 (en) * | 2013-07-17 | 2015-01-22 | The Hong Kong University Of Science And Technology | EphA4 INHIBITORS AS NEUROPROTECTIVE AGENTS |
| EP3177320B1 (en) * | 2014-07-31 | 2021-01-06 | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services | Human monoclonal antibodies against epha4 and their use |
| PE20181051A1 (es) * | 2015-09-08 | 2018-07-03 | Eisai Randd Man Co Ltd | Anticuerpo anti-epha4 |
| EP3995582B1 (en) | 2019-07-01 | 2026-04-22 | Eisai R&D Management Co., Ltd. | Anti-epha4 antibody |
-
2020
- 2020-06-29 EP EP20834769.0A patent/EP3995582B1/en active Active
- 2020-06-29 SM SM20260263T patent/SMT202600263T1/it unknown
- 2020-06-29 PE PE2021002077A patent/PE20220570A1/es unknown
- 2020-06-29 CN CN202080039114.0A patent/CN113906050B/zh active Active
- 2020-06-29 SG SG11202112433VA patent/SG11202112433VA/en unknown
- 2020-06-29 CA CA3139398A patent/CA3139398A1/en active Pending
- 2020-06-29 FI FIEP20834769.0T patent/FI3995582T3/fi active
- 2020-06-29 JP JP2021519890A patent/JP6979147B2/ja active Active
- 2020-06-29 AR ARP200101834A patent/AR119303A1/es active IP Right Grant
- 2020-06-29 US US16/915,412 patent/US10947313B2/en active Active
- 2020-06-29 LT LTEPPCT/JP2020/025465T patent/LT3995582T/lt unknown
- 2020-06-29 TW TW112123862A patent/TWI866304B/zh active
- 2020-06-29 CN CN202311449611.XA patent/CN117398459A/zh active Pending
- 2020-06-29 PH PH1/2021/553090A patent/PH12021553090A1/en unknown
- 2020-06-29 TW TW109121908A patent/TWI779307B/zh active
- 2020-06-29 WO PCT/JP2020/025465 patent/WO2021002312A1/ja not_active Ceased
- 2020-06-29 MY MYPI2021006929A patent/MY207780A/en unknown
- 2020-06-29 RS RS20260740A patent/RS68231B1/sr unknown
- 2020-06-29 PT PT208347690T patent/PT3995582T/pt unknown
- 2020-06-29 MX MX2021015298A patent/MX2021015298A/es unknown
- 2020-06-29 AU AU2020300205A patent/AU2020300205B2/en active Active
- 2020-06-29 KR KR1020217038552A patent/KR102953475B1/ko active Active
- 2020-06-29 UA UAA202106526A patent/UA129772C2/uk unknown
- 2020-06-29 TW TW111133484A patent/TWI808882B/zh active
- 2020-06-29 BR BR112021025161A patent/BR112021025161A2/pt unknown
- 2020-06-29 MA MA56466A patent/MA56466B1/fr unknown
- 2020-06-29 ES ES20834769T patent/ES3073217T3/es active Active
-
2021
- 2021-01-08 US US17/145,001 patent/US11136400B2/en active Active
- 2021-11-03 IL IL287828A patent/IL287828A/en unknown
- 2021-11-09 ZA ZA2021/08836A patent/ZA202108836B/en unknown
- 2021-11-12 JP JP2021184594A patent/JP7072114B2/ja active Active
- 2021-12-07 CO CONC2021/0016588A patent/CO2021016588A2/es unknown
- 2021-12-13 CL CL2021003326A patent/CL2021003326A1/es unknown
- 2021-12-14 JO JOP/2021/0333A patent/JOP20210333A1/ar unknown